The pediatric endocrinology clinic nurse’s communication challenge
The pediatric endocrinology clinic nurse works in a specialty defined by an unusual clinical paradox: the most urgent and consequential findings in pediatric endocrinology are almost always invisible to the family. The child in a diabetic ketoacidosis crisis looks sick — that part is legible. But the child who will develop DKA in three days because the diagnosis was delayed by a week of watchful waiting looks completely normal today. The 7-year-old with precocious puberty whose adult height will be permanently reduced by two centimeters looks healthy in every observable way. The newborn with no thyroid gland, whose brain is incapable of forming the synaptic connections that underlie language and cognition without immediate hormonal supplementation, is nursing, gaining weight, and meeting every nursing assessment criterion for a healthy newborn.
The recurring communication challenge is not that families distrust the medical team. It is that the family’s evidence — what they can see, touch, and measure about their child — points consistently in the direction of normality or improvement, and the nurse’s evidence is biological and mechanistic: invisible processes happening on a timeline that does not match clinical appearance.
Three patterns recur with particular frequency in the pediatric endocrinology clinic:
The first is the permanence paradox: a family told their child has a chronic condition expects that effective treatment will, over time, reduce the need for treatment. The child who has been treated for a bacterial infection takes fewer antibiotics as the infection resolves. The child who takes a steroid burst for asthma stops the steroids when the exacerbation clears. Type 1 diabetes inverts this expectation at the cellular level: the treatment exists because the cells that would have produced the same molecule are permanently gone, and no treatment — not insulin, not any other medication — changes that fact or reduces the requirement for replacement.
The second is the healthy-child intervention paradox: a child who appears entirely healthy is recommended a treatment involving monthly injections for two to three years. The parents’ observation is correct — the child is healthy by every metric they can access. The problem the intervention addresses is a future event whose trajectory is set now by a biological process they cannot see: the growth plates closing before the child has finished growing.
The third is the silent-urgency paradox: a newborn who appears normal, feeds normally, and passes every clinical assessment is prescribed lifelong thyroid hormone replacement within days of birth. The urgency the nurse must convey is not visible in the infant’s current presentation — it is biological and prospective, anchored in a developmental window that closes permanently without the hormone the infant’s absent thyroid cannot produce.
Three conversations from the pediatric endocrinology clinic:
Scenario 1: Marco Gutiérrez-Sandoval — 8 years old, San Antonio, Texas
Marco Gutiérrez-Sandoval had been a healthy, active third-grader until September. His parents had noticed over a period of about three weeks that he was drinking water constantly — refilling his bottle four or five times at school, waking up twice each night to use the bathroom — and that he had lost weight. His mother Elena, a school cafeteria supervisor, had attributed the thirst to the September heat and the weight loss to the start of soccer season. His father Ricardo, a plumber, had wondered aloud if Marco might be growing.
On a Tuesday morning, Marco had not wanted to get out of bed. When Elena went to wake him, his breathing was labored and deep, with a fruity smell she had not recognized. She had called 911. In the emergency department, his glucose was 487 mg/dL, his HbA1c was 13.2 percent, his pH was 7.28, and his bicarbonate was 14. He was admitted to the pediatric intensive care unit with diabetic ketoacidosis.
Over the next thirty-six hours, Marco’s glucose normalized, his acidosis resolved, and he was transferred to the general pediatric floor. By the second day, he was sitting up, eating breakfast, and asking when he could go home. The endocrinology team had made the formal diagnosis: type 1 diabetes mellitus. The diabetes education team had begun what would be a two-day inpatient education before discharge.
Elena and Ricardo sat in the education room on the second morning with a notebook Elena had bought from the hospital gift shop. She had filled the first three pages with numbers, abbreviations, and injection sites. She was thorough; she was the kind of person who prepared. But as the session was beginning, Ricardo had set his hand on the notebook and asked the question that had been in the room since the diagnosis:
“Todo lo que nos han explicado lo entendemos — la insulina, el monitor, los carbohidratos. Lo que no entendemos es el “para siempre.” Los niños crecen y se ponen fuertes. Con el tratamiento correcto — ¿el páncreas no puede recuperarse con el tiempo?” (Everything they have explained to us we understand — the insulin, the monitor, the carbohydrates. What we do not understand is the “forever.” Children grow and get strong. With the right treatment — can the pancreas not recover over time?)
Pediatric endocrinology clinic nurse Marisol Aguirre-Fuentes had been doing new-diagnosis education for nine years. She had learned that Ricardo’s question was the most important question in the room, and that answering it correctly in the first education session determined whether the family would be reaching for a cure that did not exist for the next decade or whether they would be invested in managing the condition Marco actually had.
“Don Ricardo — esa pregunta es exactamente la que esperaba, y me alegra que la hayan hecho ahora. La respuesta requiere que les explique qué tipo de enfermedad es la diabetes tipo 1, porque es diferente de lo que probablemente imaginaron cuando escucharon la palabra ‘diabetes.’” (Mr. Ricardo — that question is exactly the one I expected, and I am glad you asked it now. The answer requires that I explain what kind of disease type 1 diabetes is, because it is different from what you probably imagined when you heard the word ‘diabetes.’)
She paused. “La diabetes tipo 2, que es la que muchos adultos tienen, es una enfermedad en que el páncreas produce insulina pero el cuerpo no la usa bien. El páncreas trabaja más y más hasta que se agota. Esa diabetes responde a dieta, ejercicio, y medicamentos que ayudan al cuerpo a usar la insulina que el páncreas produce. La diabetes tipo 1 es una enfermedad diferente. No es que el páncreas trabajó demasiado o se agotó. Es que el sistema inmune de Marco — las defensas que normalmente protegen el cuerpo de virus y bacterias — atacó y destruyó las células que producen insulina en el páncreas.” (Type 2 diabetes, which is what many adults have, is a disease in which the pancreas produces insulin but the body does not use it well. The pancreas works harder and harder until it exhausts itself. That diabetes responds to diet, exercise, and medications that help the body use the insulin the pancreas produces. Type 1 diabetes is a different disease. It is not that the pancreas worked too hard or wore out. It is that Marco’s immune system — the defenses that normally protect the body from viruses and bacteria — attacked and destroyed the cells that produce insulin in the pancreas.)
Elena looked up from the notebook. “¿El sistema inmune de Marco atacó su propio páncreas?” (Marco’s immune system attacked his own pancreas?)
“Sí. Eso se llama enfermedad autoinmune. El sistema inmune identificó las células beta del páncreas — las únicas células que producen insulina — como un blanco, y durante meses o años antes del diagnóstico las fue destruyendo. Cuando Marco llegó a urgencias el martes, el 80 o 90 por ciento de esas células ya estaban destruidas. Las pocas que quedan siguen siendo atacadas por el sistema inmune. No se pueden defender porque el sistema inmune de Marco las sigue reconociendo como un blanco.” (Yes. That is called an autoimmune disease. The immune system identified the beta cells of the pancreas — the only cells that produce insulin — as a target, and for months or years before the diagnosis it was destroying them. When Marco arrived in the emergency room on Tuesday, 80 to 90 percent of those cells were already destroyed. The few that remain continue to be attacked by the immune system. They cannot defend themselves because Marco’s immune system continues to recognize them as a target.)
Ricardo was quiet. “¿Y con el tratamiento — la insulina — el sistema inmune no para de atacar?” (And with treatment — the insulin — does the immune system not stop attacking?)
“La insulina no trata el sistema inmune. La insulina reemplaza lo que las células beta ya no pueden producir. Es una diferencia importante: si fuera una infección, el antibiótico trataría la causa y la infección se resolvería. La diabetes tipo 1 no tiene un tratamiento para la causa — no existe todavía un medicamento que detenga el proceso autoinmune en los seres humanos. La insulina no cura la enfermedad; hace posible que el cuerpo de Marco funcione sin las células que la enfermedad destruyó.” (Insulin does not treat the immune system. Insulin replaces what the beta cells can no longer produce. That is an important difference: if it were an infection, the antibiotic would treat the cause and the infection would resolve. Type 1 diabetes has no treatment for the cause — there is not yet a medication that stops the autoimmune process in humans. Insulin does not cure the disease; it makes it possible for Marco’s body to function without the cells the disease destroyed.)
Elena had stopped writing. “¿Y si el páncreas tiene otras células — no las beta — que sobrevivieron?” (And if the pancreas has other cells — not the beta ones — that survived?)
“Las demás células del páncreas — las que producen enzimas digestivas, las que producen glucagón — generalmente sobreviven porque el sistema inmune de la diabetes tipo 1 apunta específicamente a las células beta. Pero las células beta no se regeneran en los niños mayores y los adultos — el cuerpo no puede producir nuevas células beta para reemplazar las que se perdieron. Las células que quedaron seguirán siendo atacadas hasta que desaparezcan. Eso no ocurre de un día para el otro — puede tardar meses o años — pero es el curso esperado.” (The other cells of the pancreas — those that produce digestive enzymes, those that produce glucagon — generally survive because the immune system in type 1 diabetes targets specifically the beta cells. But beta cells do not regenerate in older children and adults — the body cannot produce new beta cells to replace the ones that were lost. The cells that remain will continue to be attacked until they disappear. That does not happen overnight — it can take months or years — but it is the expected course.)
Ricardo leaned back. He was processing the architecture of what he had just been told: not a temporary malfunction, not a weakness that treatment could correct, but a permanent structural absence. “Entonces la insulina — para Marco — es como las lentes para alguien que tiene los ojos cortos. No corrige el problema; hace que pueda funcionar a pesar del problema.” (So insulin — for Marco — is like glasses for someone who is nearsighted. It does not fix the problem; it makes it possible to function despite the problem.)
Marisol had heard many analogies over the years, and this one was good. “Exactamente eso. Y como los lentes — si Marco usa la insulina correctamente, puede hacer todo lo que haría un niño sin diabetes. Jugar fútbol, comer, crecer, aprender. La insulina bien manejada no le quita nada a la vida de Marco — se la protege.” (Exactly that. And like glasses — if Marco uses insulin correctly, he can do everything a child without diabetes would do. Play soccer, eat, grow, learn. Well-managed insulin does not take anything from Marco’s life — it protects it.)
Elena opened the notebook to a fresh page. “Entonces el objetivo del tratamiento es que los niveles de glucosa se mantengan en rango para que Marco no tenga otra crisis y para que no haya daño en los años que vienen.” (So the treatment goal is for glucose levels to stay in range so that Marco does not have another crisis and so that there is no damage in the years ahead.)
“Exactamente eso. La crisis que tuvo Marco — la cetoacidosis — ocurre cuando no hay insulina suficiente. Con insulina bien dosificada y un buen monitoreo, esa crisis no tiene que volver a ocurrir. Y el daño a largo plazo — el que puede afectar los riñones, los ojos, los nervios en veinte o treinta años — está directamente relacionado con qué tan bien controlada estuvo la glucosa en todos esos años. Lo que hacemos hoy, lo que aprenden esta semana, importa para qué tan saludable va a ser Marco a los 30 años.” (Exactly that. The crisis Marco had — the ketoacidosis — happens when there is not enough insulin. With well-dosed insulin and good monitoring, that crisis does not have to happen again. And the long-term damage — the kind that can affect the kidneys, the eyes, the nerves in twenty or thirty years — is directly related to how well controlled the glucose was across all those years. What we do today, what you learn this week, matters for how healthy Marco will be at 30.)
Marco, who had been sitting in the corner building something with the hospital’s LEGO set, looked up. He was eight years old and had been listening more carefully than anyone had assumed.
“Mami — ¿puedo seguir jugando futíbol?” (Mom — can I keep playing soccer?)
Elena looked at Marisol. Marisol answered directly: “Sí, Marco. Los niños con diabetes tipo 1 juegan fútbol, hacen deporte, y van a las olimpiadas. Vamos a enseñarle a tu familia cómo manejar la glucosa durante el ejercicio, porque hay que ajustar la insulina cuando corres. Pero el fútbol no está prohibido — está planeado.” (Yes, Marco. Children with type 1 diabetes play soccer, do sports, and go to the Olympics. We are going to teach your family how to manage glucose during exercise, because insulin needs to be adjusted when you run. But soccer is not prohibited — it is planned.)
Marco went back to his LEGO. Elena uncapped her pen and turned to the next blank page in the notebook.
Scenario 2: Sofía Morales-Rivera — 7 years old, Los Angeles, California
Sofía Morales-Rivera’s mother Ana had noticed breast development when Sofía was 6 years and 10 months old. She had mentioned it to the pediatrician at the nine-month well-child visit and had been told to monitor and return in two months. At the two-month recheck, Sofía had progressed to Tanner 2. Underarm hair had begun. A bone age X-ray had been ordered. The result: 9.5 years at a chronological age of 7 years and 1 month. The pediatrician had referred to pediatric endocrinology that same day.
The endocrinology workup had confirmed central precocious puberty: LH 6.2 IU/L post-GnRH stimulation (a value that strongly suggested central activation), estradiol 38 pg/mL, brain MRI normal (ruling out a hypothalamic or pituitary lesion). The diagnosis was idiopathic central precocious puberty. The pediatric endocrinologist had reviewed the options with Ana and her husband Jorge, a restaurant cook, and had recommended leuprolide acetate, a GnRH agonist, 7.5 mg by intramuscular injection once per month until Sofía reached an appropriate chronological age for puberty to resume (typically 10 to 11 years).
Ana and Jorge had arrived at the nursing education appointment before the first injection with a single concern they had articulated to each other in the parking lot but had not yet said out loud in the office: Sofía looked healthy. She was doing well in school. She had friends. She played with her little sister. Nothing about her, from the outside, looked like something that required a monthly injection for the next three years.
Jorge was the one who said it. “Enfermera — nosotros entendemos que hay una diferencia en los números. Pero Sofía se ve bien. Come bien, duerme bien, está feliz. ¿Cuál es el daño que vamos a prevenir con estas inyecciones? Porque lo que vemos nosotros es una niña sana.” (Nurse — we understand there is a difference in the numbers. But Sofía looks fine. She eats well, sleeps well, she is happy. What is the harm we are going to prevent with these injections? Because what we see is a healthy girl.)
Pediatric endocrinology clinic nurse Carmen Velarde-Ortiz had been preparing for this question since she read the chart. The challenge was that Jorge’s observation was entirely accurate — Sofía looked fine today — and the harm being prevented was entirely future, measurable only in a height that would not be reached if treatment was not given.
“Don Jorge, usted tiene razón: Sofía está sana. La pubertad temprana no hace que los niños se sientan enfermos. El daño que vamos a prevenir no es algo que Sofía va a sentir ahora — es algo que le vamos a quitar si no actuamos, y que no se puede recuperar después de que ocurra. Necesito explicarles qué hace la pubertad temprana a los huesos, porque eso es lo que importa aquí.” (Mr. Jorge, you are right: Sofía is healthy. Early puberty does not make children feel sick. The harm we are going to prevent is not something Sofía will feel now — it is something we will take from her if we do not act, and that cannot be recovered after it happens. I need to explain what early puberty does to bones, because that is what matters here.)
She took a diagram from the folder in front of her — a simple illustration of a long bone with an arrow pointing to the growth plate at the end. “Los huesos crecen desde aquí: el cartílago de crecimiento, que está al final de cada hueso largo. Mientras el cartílago de crecimiento está activo, el hueso puede crecer. Cuando ese cartílago se cierra — se endurece y se convierte en hueso normal — el crecimiento termina permanentemente. No se puede reabrir.” (Bones grow from here: the growth plate, which is at the end of each long bone. While the growth plate is active, the bone can grow. When that plate closes — hardens and becomes normal bone — growth ends permanently. It cannot be reopened.)
Ana was watching the diagram. “¿Y qué cierra el cartílago?” (And what closes the cartilage?)
“Los estrógenos — la hormona femenina que produce la pubertad. Cuando el nivel de estrógenos sube y se mantiene alto durante suficiente tiempo, ese cartílago de crecimiento recibe la señal de cerrarse. En una niña que empieza la pubertad a la edad normal — 8 a 10 años — los cartílagos se cierran cuando la niña tiene 12 o 13 años de edad ósea. Pero la clave es que ese cierre ocurre en edad ósea, no en edad cronológica. Y la edad ósea de Sofía ya es 9 y medio.” (Estrogens — the female hormone that puberty produces. When estrogen levels rise and stay high long enough, the growth plate receives the signal to close. In a girl who starts puberty at the normal age — 8 to 10 years — the plates close when the girl has a bone age of 12 or 13. But the key is that that closure happens at bone age, not at chronological age. And Sofía’s bone age is already 9.5.)
Jorge was doing the math. “¿Eso significa que los cartílagos de Sofía se van a cerrar antes?” (Does that mean Sofía’s plates will close earlier?)
“Sí. Si la pubertad de Sofía continúa sin tratamiento, los estrógenos van a seguir subiendo. Los cartílagos de crecimiento van a madurar al ritmo que la edad ósea marca — no al ritmo de su edad real. Cuando llegue a edad ósea 12 o 13, los cartílagos se cerrarán — pero en ese momento, Sofía tendrá quizás 10 años cronológicos. Habrá dejado de crecer dos o tres años antes de lo que su cuerpo estaría listo. Los estudios de niñas con pubertad precoz central sin tratamiento muestran una estatura adulta promedio de 2 a 5 centímetros por debajo de la estatura genética — la estatura que sus genes le permitirían si los cartílagos tuvieran el tiempo completo.” (Yes. If Sofía’s puberty continues without treatment, estrogens will keep rising. The growth plates will mature at the rate the bone age marks — not at the rate of her actual age. When she reaches bone age 12 or 13, the plates will close — but at that point, Sofía will be perhaps 10 chronological years old. She will have stopped growing two or three years earlier than her body would be ready. Studies of girls with untreated idiopathic central precocious puberty show an average adult height 2 to 5 centimeters below the genetic target height — the height her genes would allow if the plates had their full time.)
Ana was thinking about something specific. “¿2 o 5 centímetros — eso es mucho?” (2 to 5 centimeters — is that a lot?)
“Depende de la perspectiva. En términos de salud — tener 158 centímetros en lugar de 162 no cambia nada en la salud de Sofía. Pero es estatura que se puede preservar si actuamos ahora, y que no se puede recuperar después de que los cartílagos cierren. Lo que no podemos deshacer después de que ocurra, lo prevenimos ahora si podemos. Esa es la razón del tratamiento.” (It depends on the perspective. In health terms — being 158 centimeters instead of 162 does not change anything about Sofía’s health. But it is height that can be preserved if we act now, and that cannot be recovered after the plates close. What cannot be undone after it happens, we prevent now if we can. That is the reason for treatment.)
Jorge had one more question. “¿Y el leuprolide — la inyección — cómo funciona?” (And leuprolide — the injection — how does it work?)
“El cerebro controla la pubertad con una señal que se llama GnRH, que activa una cadena hormónica que termina produciendo estrógenos. El leuprolide imita esa señal, pero en lugar de darla en pulsos como el cuerpo lo hace, la da de manera continua. Cuando el receptor recibe la misma señal sin descanso, se cansa y deja de responder — es una paradoja: estimular continuamente produce el mismo efecto que bloquear. El resultado es que los estrógenos bajan, la pubertad se detiene, y los cartílagos de crecimiento dejan de recibir la señal de madurar.” (The brain controls puberty with a signal called GnRH, which activates a hormonal chain that ends by producing estrogens. Leuprolide mimics that signal, but instead of giving it in pulses the way the body does, it gives it continuously. When the receptor receives the same signal without rest, it tires and stops responding — it is a paradox: continuous stimulation produces the same effect as blocking. The result is that estrogens fall, puberty stops, and the growth plates stop receiving the signal to mature.)
Ana looked at Sofía, who was sitting in the chair next to her, drawing a horse in her notebook, apparently unconcerned. “¿Y cuando paramos el tratamiento?” (And when we stop the treatment?)
“Cuando Sofía llegue a los 10 u 11 años — la edad apropiada para que empiece la pubertad — paramos el leuprolide. En semanas, la señal del cerebro vuelve a funcionar en pulsos, los estrógenos suben, y la pubertad continúa normalmente. El leuprolide no detiene la pubertad para siempre — la pausa. Sofía va a vivir su pubertad completa, su fertilidad normal, su desarrollo normal — simplemente a la edad correcta. Lo que preservamos con el tratamiento no es la infancia — es la estatura.” (When Sofía reaches 10 or 11 years — the appropriate age for puberty to begin — we stop the leuprolide. Within weeks, the brain’s signal returns to pulsing, estrogens rise, and puberty continues normally. Leuprolide does not stop puberty forever — it pauses it. Sofía will live her complete puberty, normal fertility, normal development — simply at the right age. What we preserve with treatment is not childhood — it is height.)
Sofía had looked up from her horse drawing when she heard her name. “Mami, ¿la inyección duele?” (Mom, does the injection hurt?)
Carmen answered before Ana could. “Un poquito, como las demás vacunas. Pero es una vez al mes — y después puedes escoger una calcomanía.” (A little, like the other vaccines. But it is once a month — and afterward you can choose a sticker.)
Sofía considered this carefully. “¿Pueden ser calcomanías de caballos?” (Can they be horse stickers?)
“Puedo traer caballos la próxima vez,” Carmen said. (I can bring horses next time.)
Scenario 3: Valentina Cruz-Peña — 3 weeks old, Houston, Texas
Valentina Cruz-Peña had been born at 39 weeks and three days at Memorial Hermann Hospital in Houston. Her birth weight was 3.2 kilograms. Her APGAR scores were 8 and 9. She had latched immediately and was nursing every two to three hours. At her three-day newborn visit, she had been back to birth weight. Her jaundice had resolved. Her pediatrician had found her examination entirely normal at the two-week check.
On a Tuesday afternoon, Claudia — 24, a pharmacy technician — had received a call from the pediatric endocrinology department at Texas Children’s Hospital. The state newborn screening panel, performed from Valentina’s heel-stick blood on day 2, had flagged a critically elevated TSH — thyroid-stimulating hormone. They needed a same-day venous confirmation draw. Could she bring Valentina in today?
The confirmatory labs had come back the same evening: TSH 242 mIU/L (normal in neonates below 20), free T4 0.4 ng/dL (normal above 1.0). The thyroid ultrasound ordered the same day showed no thyroid tissue in the normal location or along the thyroglossal duct. Thyroid agenesis — Valentina had no thyroid gland at all. The fellow had called Claudia at 7 PM with the results and had started levothyroxine by prescription that evening.
Two days later, Claudia and her husband Andrés — 27, an HVAC technician — were in the pediatric endocrinology clinic for the formal diagnosis appointment. They had driven through rush-hour traffic to get there. Valentina was in the carrier, nursing normally, moving her arms and legs, tracking Ana’s face across the room with perfect newborn alertness.
Andrés had been quiet on the drive. In the waiting room, he had told Claudia what he had been carrying for two days: “El bebé se ve bien. Niños que están enfermos — se ve. Este bebé no se ve enfermo.” (The baby looks fine. Children who are sick — you can see it. This baby does not look sick.)
Claudia, who worked in a pharmacy and had a more calibrated skepticism of anything that involved the word “normal,” had a different worry: the word “urgent.” The fellow had used it. The call had come at 7 PM. A same-day appointment had materialized for a lab value from a blood spot on a paper card. None of those things happened in her experience when the answer was “we’ll watch it.”
Pediatric endocrinology clinic nurse Patricia Herrera-Sandoval had reviewed the chart before coming in. Thyroid agenesis. TSH 242. Free T4 0.4. Three weeks old. She had done this conversation many times, and she had learned that there were always two conversations to have in the same room: the father’s “she looks normal” and the mother’s “why was it urgent.”
“Claudia, Andrés — voy a explicarles por qué llamamos tan rápido, por qué empezamos el medicamento esa misma noche, y por qué Valentina se ve completamente normal. Las tres cosas están relacionadas.” (Claudia, Andrés — I am going to explain why we called so quickly, why we started the medication that same night, and why Valentina looks completely normal. The three things are connected.)
She had brought a simple illustration — a cross-section of a developing brain, labeled with the key structures. “La hormona tiroidea — T3, que el cuerpo produce a partir de la T4 que le damos en el medicamento — es la señal que le dice al cerebro en desarrollo que haga su trabajo. No cualquier trabajo: tres cosas muy específicas. Primero, la migración neuronal: las células del cerebro tienen que viajar desde donde nacen hasta el lugar donde van a funcionar, que está a distancias muy largas en términos microscópicos. La hormona tiroidea es parte de la señal que guía ese viaje. Segundo, la mielinización: cada nervio en el cerebro necesita una vaina de mielina, que es como el aislante de un cable eléctrico. Sin esa vaina, la señal eléctrica no viaja bien. La hormona tiroidea es lo que activa la formación de esa vaina en el primer año de vida — sobre todo en ese primer año. Tercero, las conexiones sinápticas: las ramas de las células del cerebro que forman las conexiones que permiten pensar, hablar, recordar, y aprender. Esas ramas crecen en los primeros tres años de vida, con el primer año siendo el más crítico. Necesitan la hormona tiroidea para hacerlo.” (Thyroid hormone — T3, which the body produces from the T4 we give in the medication — is the signal that tells the developing brain to do its work. Not just any work: three very specific things. First, neuronal migration: the brain cells have to travel from where they are born to the place where they will function, which is very long distances in microscopic terms. Thyroid hormone is part of the signal that guides that journey. Second, myelination: each nerve in the brain needs a myelin sheath, which is like the insulation of an electrical cable. Without that sheath, the electrical signal does not travel well. Thyroid hormone is what activates the formation of that sheath in the first year of life — especially in that first year. Third, synaptic connections: the branches of brain cells that form the connections that allow thinking, speaking, remembering, and learning. Those branches grow in the first three years of life, with the first year being the most critical. They need thyroid hormone to do it.)
Andrés had stopped looking at Valentina and was looking at Patricia. “¿Y Valentina no tiene tiroides?” (And Valentina has no thyroid?)
“No tiene. La tiroides es la glándula en el cuello que normalmente produce la hormona tiroidea. El ultrasonido mostró que Valentina nació sin ella — se llama agenesia tiroidea. Es una condición que ocurre en aproximadamente 1 de cada 4,000 bebés. Valentina no tiene un gen defectuoso que ustedes pasaron — simplemente la glándula no se formó durante el embarazo. Sin la tiroides, el cuerpo de Valentina no puede producir la hormona tiroidea que su cerebro necesita en este momento.” (She has none. The thyroid is the gland in the neck that normally produces thyroid hormone. The ultrasound showed that Valentina was born without one — it is called thyroid agenesis. It is a condition that occurs in approximately 1 in 4,000 babies. Valentina does not have a defective gene that you passed on — the gland simply did not form during pregnancy. Without the thyroid, Valentina’s body cannot produce the thyroid hormone her brain needs right now.)
Claudia was thinking carefully. “¿Y el medicamento que empezamos — la levotiroxina — reemplaza la hormona?” (And the medication we started — levothyroxine — replaces the hormone?)
“Exactamente. La levotiroxina es T4 sinética — la misma molécula que la tiroides sana produciría, solo que fabricada en un laboratorio. El cuerpo de Valentina la convierte en T3 activa, igual que lo haría con la hormona natural. Desde la primera dosis, el cerebro de Valentina tiene la señal que necesita para empezar su trabajo.” (Exactly. Levothyroxine is synthetic T4 — the same molecule a healthy thyroid would produce, just made in a laboratory. Valentina’s body converts it to active T3, just as it would with the natural hormone. From the first dose, Valentina’s brain has the signal it needs to start its work.)
Andrés returned to his question. “Pero ella se ve bien.” (But she looks fine.)
“Sí. Y ahí está la clave de por qué actuamos tan rápido.” Patricia chose her words carefully. “Valentina se ve bien porque el daño todavía no ocurrió. El trabajo que el cerebro de Valentina tiene que hacer en el primer año — mielinizar los nervios, formar las conexiones — todavía no está programado para este momento. Está programado para las próximas semanas, los próximos meses. Los retrasos del desarrollo — el lenguaje, el pensamiento, el movimiento — no aparecerían hasta los 12 o 18 meses, cuando esperamos ver esas habilidades. Para ese momento, si no hubiéramos empezado el tratamiento, el daño ya habría ocurrido durante el período en que era prevenible.” (Yes. And there is the key to why we acted so quickly. Valentina looks fine because the damage has not yet happened. The work Valentina’s brain has to do in the first year — myelinating nerves, forming connections — is not yet scheduled for this moment. It is scheduled for the coming weeks, the coming months. The developmental delays — language, thought, movement — would not appear until 12 or 18 months, when we expect to see those skills. By that time, if we had not started treatment, the damage would already have occurred during the period when it was preventable.)
The room was quiet. Andrés looked at Valentina, who had finished nursing and was looking up at the ceiling light with focused newborn attention.
“Antes de que existieran los tamices neonatales — antes de los años ochenta, cuando se implementaron en México y en Estados Unidos — los bebés que nacían sin tiroides y no eran diagnosticados no se verían diferentes a Valentina en las primeras semanas de vida. A los 18 meses, la diferencia era irreversible. El tamiz neonatal existía para que lo que le pasó a esos bebés no le volviera a pasar a ninguno más — porque si llegamos antes de que el daño empiece, el resultado es casi normal.” (Before newborn screening existed — before the 1980s, when it was implemented in Mexico and in the United States — babies born without a thyroid who were not diagnosed would not have looked different from Valentina in the first weeks of life. At 18 months, the difference was irreversible. Newborn screening existed so that what happened to those babies would not happen to any more — because if we arrive before the damage begins, the outcome is nearly normal.)
Claudia was still very still. “¿Casi normal?” (Nearly normal?)
Patricia did not flinch from the qualifier. “El resultado depende de qué tan pronto empieza el tratamiento y qué tan bien se mantiene el nivel de T4 en rango óptimo en el primer año. Los estudios muestran que los bebés con hipotiroidismo congénito detectado en el tamiz y tratados en las primeras dos semanas de vida tienen un desarrollo intelectual y del lenguaje que no se puede distinguir del de los niños sin la condición. Valentina empezó tratamiento a las tres semanas — que es dentro de la ventana donde los resultados son excelentes. Lo que haremos de aquí en adelante es verificar los niveles cada cuatro a seis semanas en el primer año, ajustar la dosis según el crecimiento de Valentina, y mantener el nivel de T4 libre en el rango óptimo para el desarrollo del cerebro. El seguimiento frecuente en el primer año es la diferencia.” (The outcome depends on how soon treatment begins and how well T4 levels are maintained in the optimal range in the first year. Studies show that babies with congenital hypothyroidism detected on screening and treated within the first two weeks of life have intellectual and language development that cannot be distinguished from children without the condition. Valentina started treatment at three weeks — which is within the window where outcomes are excellent. What we will do from here is check levels every four to six weeks in the first year, adjust the dose as Valentina grows, and keep the free T4 level in the optimal range for brain development. Frequent follow-up in the first year is the difference.)
Claudia looked at the small pill on the instruction sheet. “¿Cómo le doy la pastilla a un bebé de tres semanas?” (How do I give a pill to a three-week-old?)
“La pastilla se aplasta y se disuelve en una pequeña cantidad de leche materna o agua — no mucha, solo unas pocas gotas, para que pueda asegurarse de que Valentina la toma toda. No se puede disolver en una botella entera porque no se garantiza que tome toda la dosis. Se da en la misma hora todos los días — para que el nivel sea estable. Y si Valentina escupe la dosis o vomita dentro de los primeros 30 minutos, se repite esa misma vez — no se espera a la siguiente.” (The pill is crushed and dissolved in a small amount of breast milk or water — not much, just a few drops, so you can make sure Valentina takes all of it. It cannot be dissolved in a full bottle because you cannot guarantee she takes the full dose. It is given at the same time every day — so that the level is stable. And if Valentina spits out the dose or vomits within the first 30 minutes, it is repeated that same time — not waited until the next day.)
Andrés was writing in the notes app on his phone. Claudia was watching him and then looked at Patricia. “Ella viene conmigo al trabajo a veces. ¿Hay que hacer algo diferente?” (She comes with me to work sometimes. Is there anything different to do?)
“La levotiroxina no tiene restricciones en la actividad ni en la exposición. Valentina puede ir donde la llevan. La única precaución práctica es no dar la pastilla en la misma hora que un bibérón con fórmula de soya o con multivitaminas con hierro, porque esas cosas reducen la absorción. Lo más fácil es darla a primera hora de la mañana, antes del primer bibérón o la primera toma.” (Levothyroxine has no restrictions on activity or exposure. Valentina can go where you take her. The only practical precaution is not to give the pill at the same time as a bottle with soy formula or multivitamins with iron, because those things reduce absorption. The easiest thing is to give it first thing in the morning, before the first bottle or feeding.)
Andrés looked up from his phone. He was thirty-eight steps into a new daily routine he had not anticipated two weeks ago. “Primera hora de la mañana. Pastilla aplastada en pocas gotas de leche. Nivel de T4 cada cuatro a seis semanas. Si vomita en los primeros 30 minutos, repetir.” (First thing in the morning. Pill crushed in a few drops of milk. T4 level every four to six weeks. If she vomits within the first 30 minutes, repeat.)
“Exactamente eso,” Patricia said. (Exactly that.)
Valentina had fallen asleep in the carrier, her hand wrapped around the strap, her breathing even and slow. Claudia looked at her for a long moment.
“La tamizó cuando nació y encontramos lo que se necesitaba encontrar. De aquí en adelante, el trabajo es mantener el nivel correcto para que su cerebro tenga lo que necesita. Y su cerebro, con eso, va a hacer exactamente lo que tiene que hacer.” Patricia said quietly. (The screen found her when she was born and found what needed to be found. From here on, the work is maintaining the right level so her brain has what it needs. And her brain, with that, will do exactly what it needs to do.)
Andrés closed the notes app. “Entonces el objetivo — una T4 en rango en cada chequeo — es lo que hace que Valentina llegue a los dos años sin diferencia.” (So the goal — a T4 in range at every checkup — is what makes Valentina reach age 2 without a difference.)
“Ese es exactamente el objetivo,” Patricia said. (That is exactly the goal.)